> Skip repeated content

Database of the Gosden Robinson Early Arthritis Center (EAC): Analysis of Types of Patients Recruited to an Urban EAC

IRB Number: 24067
(inactive trial)

Institutional Review Board, Hospital for Special Surgery

February 05, 2007

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Lisa C. Vasanth, MD

Co-Investigators

Stephen Paget, MD
Theodore Fields, MD
Melanie J. Harrison, MD
Karen Golan, M.Ed
Janine Fernandez
Debbie Miller
Ania Rodney
Katy Flynn-Meketon
Jamie Weiss

Summary

This registry is a database of patients with early signs of arthritis and inflammation. Enrollment period is continuous and ongoing. Recruitment is continuous and ongoing. Patients in the registry may also qualify for future qualitative research projects, at which point they would be contacted for follow up. All that is required of patients in order to enroll in the database is complete a short questionnaire.

Inclusion/Exclusion Criteria

Patients must have inflammatory symptoms for <1 year.

Contact Information

Karen Golan, MEd
212.744.7339